AstraZeneca

Piper Jaffray provided color on biotechnology. In a research report published today, Piper Jaffray commented on two new drugs, Novo Nordisk's degludec and BMS and AstraZeneca's dapagliflozin. In the report, Piper Jaffray states, “We attended the American Diabetes Association conference, where...

AstraZeneca (NYSE: AZN) shares were up in early trading after Morgan Stanley (NYSE: MS) upgraded the drugmaker's stock to Overweight from Equalweight late Wednesday. "Worsening generic pressure and R&D management changes lead us to expect material cuts to internal small research spend in 2010/...